SCHEMBL7906647

SCHEMBL7906647

CN(C)C(=O)C[C@H](N)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GRIK1 P39086 9/20 0.54
▸ SLC7A5 Q01650 1/20 0.50
▸ GRIK2 Q13002 5/20 0.48
▸ GRM1 Q13255 1/20 0.46
▸ GRM2 Q14416 1/20 0.46
▸ GRIA4 P48058 3/20 0.45
▸ GRIK3 Q13003 3/20 0.45
▸ GRIK5 Q16478 3/20 0.45
▸ SLC1A3 P43003 4/20 0.45
▸ SLC1A2 P43004 4/20 0.45
▸ SLC1A1 P43005 3/20 0.45
▸ GRIA2 P42262 2/20 0.44
▸ GRIA1 P42261 1/20 0.44
▸ PTGS1 P23219 1/20 0.42
▸ SLC7A11 Q9UPY5 1/20 0.42
▸ GGT1 P19440 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL197013 1.00 GRIK1 (0.54) GRIK1SLC7A5GRIK2GRM1GRM2
Trifluoroacetic Acid SCHEMBL30191327 0.88 GRIK1 (0.44) GRIK1SLC7A5GRIK2GRM1GRM2
SCHEMBL13913802 0.81 DPP9 (0.39) GRIK1SLC7A5GRIK2
SCHEMBL13913742 0.81 DPP9 (0.39) GRIK1SLC7A5GRIK2
SCHEMBL1768449 0.77 GSR (0.58) GRIK1GRIK2GRM1GRM2GRIA4
SCHEMBL197385 0.77 GSR (0.58) GRIK1GRIK2GRM1GRM2GRIA4
SCHEMBL3096327 0.77 ALDH1A1 (0.39) GRIK1
SCHEMBL1768719 0.77 GRIK1 (0.46) GRIK1SLC7A5GRIK2GRM1GRM2
SCHEMBL1768717 0.77 GRIK1 (0.46) GRIK1SLC7A5GRIK2GRM1GRM2
Aspartic Acid SCHEMBL16027034 0.77 GRIK1 (0.42) GRIK1SLC7A5GRIK2GRM1GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025100520-A1 PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE ペプチドリーム株式会社 2025-05-15 — — WO claimed
EP-4724457-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Rayzebio, Inc. (US) 2026-04-15 — — EP disclosed
EP-4724459-A1 PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Peptidream Inc (JP) 2026-04-15 — — EP disclosed
US-20260098061-A1 EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME PEPTIDREAM INC (JP) 2026-04-09 — — US disclosed
EP-4684030-A2 METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP Martin-Luther-Universität Halle-Wittenberg (DE) 2026-01-28 — — EP disclosed
EP-4667483-A1 HUMAN TRANSFERRIN RECEPTOR-BINDING PEPTIDE JCR Pharmaceuticals Co., Ltd. (JP) 2025-12-24 — — EP disclosed
WO-2024254339-A9 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF RAYZEBIO, INC. (US) 2025-10-16 — — WO disclosed
WO-2025100520-A1 PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE ペプチドリーム株式会社 2025-05-15 — — WO disclosed
US-20250152658-A1 CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA MERCK SHARP & DOHME LLC (US) 2025-05-15 — — US disclosed
WO-2024252336-A1 PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF PEPTIDREAM INC. (JP) 2024-12-12 — — WO disclosed
CN-117957240-A Human transferrin receptor binding peptides 肽梦想株式会社 2024-04-30 — — CN disclosed
WO-2024073622-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF RAYZEBIO, INC. (US) 2024-04-04 — — WO disclosed
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF RAYZEBIO, INC. 2023-05-25 — — US disclosed
WO-2023022234-A1 HUMAN TRANSFERRIN RECEPTOR–BINDING PEPTIDE ペプチドリーム株式会社 2023-02-23 — — WO disclosed
CN-113853383-A Immunomodulator 百时美施贵宝公司 2021-12-28 — — CN disclosed
US-6194143-B1 MEASUREMENT ACTIVITY BY MONITORING SUBSTRATE CLEAVAGE BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2001-02-27 — — US disclosed
EP-0948640-A2 IMPROVED SUBSTRATES FOR HUMAN CYTOMEGALOVIRUS PROTEASE BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 1999-10-13 — — EP disclosed
WO-1998029562-A2 IMPROVED SUBSTRATES FOR HUMAN CYTOMEGALOVIRUS PROTEASE BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 1998-07-09 — — WO disclosed
EP-0438873-A1 Inhibitor of ribonucleotide reductase of herpes viruses MERCK & CO. INC. (US) 1991-07-31 — — EP disclosed
EP-0383190-A2 Ribonucleotide reductase inhibitors BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1990-08-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098061-A1 EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME EPHA2, EPHA1, EPHB1 GRIK1 1342/4885SLC7A5 3300/4885GRIK2 1549/4885
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF PAICS, LNPEP, DNPEP GRIK1 2914/4885SLC7A5 75/4885GRIK2 3197/4885
US-20250152658-A1 CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA IL1R1, IL1A, IL1B GRIK1 3814/4885SLC7A5 4199/4885GRIK2 4818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback